Engaging a patient's own cancer-specific immune system is the most promising strategy for tumor therapies currently in development. There are more and more success stories of cancer treatments by immune cell modulating therapies.
At TheryCell we are employing a new approach to learn from patients‘ own T-cells how to direct them against their individual cancers. It is our strong believe that following these lines we can implement novel, safe and highly effective personalized therapies for solid tumors.
Why Immune Therapy for Cancer Treatments?
The insight that the immune system is capable of eliminating malignant cells has stimulated the development of a variety of immunotherapeutic approaches. During the last decades, this has resulted in clinically proven treatments for many cancers. Particularly successful and revolutionary was the more recent introduction of checkpoint inhibitors which effectively restore the function of silenced T-cells. In some of the patients they induce a complete and durable response with the hope of permanent cure. Nevertheless, checkpoint inhibitors show activity only in a sub-fraction of patients and due to their underlying mechanism they increase the risk of autoimmunity. There is, therefore, still the need for effective treatments with much broader activity and high tumor specificity.